Sanofi’s Scientific Leadership in Inflammatory Diseases Showcased with New Data at AAAAI Presentation

Sanofi’s Leading Role in Addressing Inflammatory Diseases Highlighted at AAAAI Conference

The latest data presented at the American Academy of Allergy Asthma and Immunology (AAAAI) Annual Meeting sheds light on Sanofi’s robust scientific leadership in managing inflammatory diseases.

Among the key findings, late-breaking Dupixent® data utilizes innovative imaging technology to assess how Dupixent enhances lung function in patients with uncontrolled moderate-to-severe asthma. Additionally, multiple oral presentations underscore the potential of Dupixent to alleviate symptoms in individuals with eosinophilic esophagitis from as young as one year old to adulthood.

Furthermore, the conference marks the first presentation of Phase 2 data for Sanofi’s novel investigational oral BTK inhibitor, rilzabrutinib, in chronic spontaneous urticaria (CSU), laying the groundwork for a Phase 3 program.

Sanofi’s comprehensive presence at the event reflects its ongoing dedication to advancing therapies across various inflammatory conditions. The company will present twenty-three abstracts covering approved and investigational medicines, with a focus on Dupixent across six inflammatory diseases, including asthma, atopic dermatitis, eosinophilic esophagitis, eosinophilic gastritis, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria.

Dr. Naimish Patel, Global Head of Development for Immunology and Inflammation at Sanofi, expressed pride in the company’s broad scientific involvement at AAAAI. He emphasized Sanofi’s commitment to advancing Dupixent’s science while introducing disruptive mechanisms of action to address unmet medical needs.

Highlighted presentations include:

  • Advancements in the treatment of chronic spontaneous urticaria.
  • Positive data from the RILECSU Phase 2 Dose-Ranging Study demonstrating the efficacy of rilzabrutinib in improving symptoms in adults with moderate-to-severe CSU.
  • New insights into Dupixent’s impact on lung function using functional respiratory imaging.
  • Positive results from Dupixent trials in eosinophilic esophagitis, including the KIDS Phase 3 trial and the LIBERTY-EoE-TREET study.
  • Notable abstracts from other therapeutic areas, including atopic dermatitis and chronic rhinosinusitis with nasal polyps.

The AAAAI 2024 presentations encompass a range of studies and trials across various inflammatory diseases, showcasing Sanofi’s ongoing efforts to advance scientific understanding and therapeutic options in this critical area of healthcare.

Source Link